AzTrials
AzTrials

Suicidal BehaviorSAFENCT07422493

Suicidal Behavior in Adolescents and Executive Functions

A study testing Neuropsychological Tests and Psychiatric Tests in people with Suicidal Behavior and Adolescent, run by University Hospital, Angers at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Suicide is a major public health concern, particularly among young people. In France, around 400 adolescents die by suicide every year, and suicide attempts are most frequent during adolescence. Read more about this study

Who is it for?
Ages 11 to 16 years
Conditions the study is for
Suicidal Behavior, Adolescent
What is being tested?
Neuropsychological Tests and Psychiatric Tests
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteFrance
Study dates
May 2026to Oct 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 11 to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Adolescents aged 11 to 16 years (inclusive), hospitalized at Angers University Hospital in the Child or Adolescent Surgery and Medicine units for the management of suicidal behaviors (suicide attempts and/or suicidal ideation)
  • Covered by the national health insurance system
  • Assent of the adolescent
  • Written informed consent provided by the legal guardians to participate in the study

Who cannot join

  • Complete inability to complete the questionnaires (Non-communicative patient; Severe comprehension or communication disorders, Limited or no understanding of the French language)
  • Participation in another interventional study that modifies clinical care
  • Presence of a neurological condition likely to significantly impair cognitive functioning (e.g., epilepsy, brain tumor, neurometabolic disease)
  • Previous inclusion in this study during an earlier hospitalization

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Elise RIQUIN, Professor contact

02 41 35 44 42

Elise.Riquin@chu-angers.fr

France1 site
  • CHU Angers

    Angers

    Elise Riquin, Professor, 02 41 35 44 42, Elise.Riquin@chu-angers.fr

Other trials in France

About this study

Suicide is a major public health concern, particularly among young people. In France, around 400 adolescents die by suicide every year, and suicide attempts are most frequent during adolescence. This stage of life is marked by profound emotional, social, and biological changes, which can increase vulnerability to stress and psychological distress.

Current research shows that suicidal behaviors do not result from a single cause. Instead, they emerge from a complex interaction between individual vulnerabilities and stressful life events. Among these vulnerabilities, cognitive functioning-and more specifically executive functions-has attracted growing scientific interest.

Read more

Executive functions refer to a set of high-level mental abilities that allow individuals to regulate their thoughts, emotions, and actions. They include skills such as controlling impulses, adapting to new situations, planning ahead, and holding information in mind. These abilities are essential for everyday life, school learning, social interactions, and emotional regulation. Importantly, the brain networks supporting executive functions continue to develop throughout adolescence, making them particularly sensitive to psychological and environmental challenges.

In adults, several studies have shown that people with suicidal ideation or a history of suicide attempts often present difficulties in executive functioning. Such difficulties may contribute to poorer emotional regulation, increased rumination, reduced impulse control, and impaired decision-making during periods of crisis. However, in adolescents, research in this area remains limited, often involving small samples or focusing on only one or two cognitive abilities.

The main aim of this study is therefore to better understand the relationship between executive functions and suicidal behaviors in adolescents, using a comprehensive assessment tool specifically designed and validated for children and teenagers. This tool allows for a global evaluation of key executive components, including inhibition, working memory, cognitive flexibility, and planning.

A secondary objective of the study is to compare executive functioning between adolescents who experience suicidal thoughts and those who have attempted suicide. Some findings in adults suggest that these two groups may show different cognitive profiles, but this distinction has rarely been explored in younger populations.

In addition, cognitive difficulties may not only appear during testing but also have a real-life impact, affecting academic performance, emotional regulation, and social relationships. For this reason, the study also examines how executive difficulties affect everyday functioning, by collecting information from adolescents themselves, their parents, and the school environment.

Finally, suicidal behaviors in adolescents are influenced by many other factors, particularly psychiatric disorders such as depression, anxiety, and the consequences of traumatic experiences. Depression, in particular, is one of the strongest risk factors for suicide. This study therefore also aims to explore how these psychiatric conditions may influence executive functioning and shape the relationship between cognitive difficulties and suicidal behavior.

By improving our understanding of these mechanisms, this research seeks to support the development of more effective prevention strategies and better-targeted clinical interventions for adolescents at risk.

Being tested
Neuropsychological Tests and Psychiatric Tests
Keywords
adolescent, Executive functions, suicide
Medical subject headings
Suicide

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Neuropsychological Tests and Psychiatric TestsOther

    WISC V Children Executive Functions Battery BRIEF 2 C-SSRS SNAP IV CDI R-CMAS

Study groups in NCT07422493
Study groupRoleWhat they receive
Adolescents with suicidal behaviorsOtherNot described
Receives: Other: Neuropsychological Tests and Psychiatric Tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevalence of executive functioning impairment in adolescents presenting suicidal behaviors, ranging from suicidal ideation to suicide attempts

    Scores obtained on the composite indices of the FEE battery will be used to determine the presence of executive function impairment. Adolescents scoring at or above the 90th percentile for their age and sex on at least one of the four domains assessed by the FEE battery will be considered as presenting executive function impairment.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Feb 2026
  2. Study startMay 2026 (estimated)
  3. Primary completionSep 2027 (estimated)
  4. Study completionOct 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07422493
Sponsor's protocol ID
49RC25_0479
Other IDs
ANSM
Acronym
SAFE
Status last verified
Apr 2026
First submitted
12 Jan 2026
Last updated
7 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.

Questions about this trial

What is this clinical trial studying?

A study testing Neuropsychological Tests and Psychiatric Tests in people with Suicidal Behavior and Adolescent, run by University Hospital, Angers at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Elise RIQUIN, Professor (02 41 35 44 42, Elise.Riquin@chu-angers.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prevalence of executive functioning impairment in adolescents presenting suicidal behaviors, ranging from suicidal ideation to suicide attempts (time frame: Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in